• 1
    Vogelzang NJ. Emerging insights into the biology and therapy of malignant mesothelioma. Semin Oncol 2002; 29: 3542.
  • 2
    Hesdorffer ME, Chabot JA, Keohan ML, Fountain K, Talbot S, Gabay M, Valentin C, Lee SM, Taub RN. Combined resection, intraperitoneal chemotherapy, and whole abdominal radiation for the treatment of malignant peritoneal mesothelioma. Am J Clin Oncol 2008; 31: 4954.
  • 3
    Van der Speeten K, Stuart OA, Mahteme H, Sugarbaker PH. A pharmacologic analysis of intraoperative intracavitary cancer chemotherapy with doxorubicin. Cancer Chemother Pharmacol 2009; 63: 799805.
  • 4
    Richards WG, Zellos L, Bueno R, Jaklitsch MT, Janne PA, Chirieac LR, Yeap BY, Dekkers RJ, Hartigan PM, Capalbo L, Sugarbaker DJ. Phase I to II study of pleurectomy/decortication and intraoperative intracavitary hyperthermic cisplatin lavage for mesothelioma. J Clin Oncol 2006; 24: 15617.
  • 5
    van Ruth S, van Tellingen O, Korse CM, Verwaal VJ, Zoetmulder FA. Pharmacokinetics of doxorubicin and cisplatin used in intraoperative hyperthermic intrathoracic chemotherapy after cytoreductive surgery for malignant pleural mesothelioma and pleural thymoma. Anticancer Drugs 2003; 14: 5765.
  • 6
    Pass H, Carbone M, Vogelzang N. Malignant mesothelioma: advances in pathogenesis, diagnosis, and translational therapies. New York: Springer Science and Business Media, Inc., 2005: 854.
  • 7
    Sterman DH, Albelda SM. Advances in the diagnosis, evaluation, and management of malignant pleural mesothelioma. Respirology 2005; 10: 26683.
  • 8
    Grondin SC, Sugarbaker DJ. Pleuropneumonectomy in the treatment of malignant pleural mesothelioma. Chest 1999; 116: 450S4S.
  • 9
    Krug LM. An overview of chemotherapy for mesothelioma. Hematol Oncol Clin North Am 2005; 19: 111736, vii.
  • 10
    Tomek S, Emri S, Krejcy K, Manegold C. Chemotherapy for malignant pleural mesothelioma: past results and recent developments. Br J Cancer 2003; 88: 16774.
  • 11
    Mukohara T, Civiello G, Johnson BE, Janne PA. Therapeutic targeting of multiple signaling pathways in malignant pleural mesothelioma. Oncology 2005; 68: 50010.
  • 12
    Steele JPC, Rudd RM. Systemic chemotherapy for malignant pleural mesothelioma. In: O'ByrneK, RuschV, eds. Malignant pleural mesothelioma. Oxford: Oxford University Press, 2006. 297313.
  • 13
    Bartlett DW, Su H, Hildebrandt IJ, Weber WA, Davis ME. Impact of tumor-specific targeting on the biodistribution and efficacy of siRNA nanoparticles measured by multimodality in vivo imaging. Proc Natl Acad Sci USA 2007; 104: 1554954.
  • 14
    Feazell RP, Nakayama-Ratchford N, Dai H, Lippard SJ. Soluble single-walled carbon nanotubes as longboat delivery systems for platinum(IV) anticancer drug design. J Am Chem Soc 2007; 129: 84389.
  • 15
    Liu Z, Chen K, Davis C, Sherlock S, Cao Q, Chen X, Dai H. Drug delivery with carbon nanotubes for in vivo cancer treatment. Cancer Res 2008; 68: 665260.
  • 16
    Pantarotto D, Briand JP, Prato M, Bianco A. Translocation of bioactive peptides across cell membranes by carbon nanotubes. Chem Commun (Camb) 2004: 167.
  • 17
    Oberdorster G, Maynard A, Donaldson K, Castranova V, Fitzpatrick J, Ausman K, Carter J, Karn B, Kreyling W, Lai D, Olin S, Monteiro-Riviere N, et al. Principles for characterizing the potential human health effects from exposure to nanomaterials: elements of a screening strategy. Part Fibre Toxicol 2005; 2: 8.
  • 18
    Blumen SR, Cheng K, Ramos-Nino ME, Taatjes DJ, Weiss DJ, Landry CC, Mossman BT. Unique uptake of acid-prepared mesoporous spheres by lung epithelial and mesothelioma cells. Am J Respir Cell Mol Biol 2007; 36: 33342.
  • 19
    Gallis KW, Landry CC. Mesoporous silica and method of making same, US Patent 6,334,988. United States; 2002.
  • 20
    Solberg SM, Landry CC. Adsorption of DNA into mesoporous silica. J Phys Chem B 2006; 110: 152618.
  • 21
    Guthrie GD, Jr., Mossman BT. Health effects of mineral dusts, vol. 28. Washington, DC: Mineralogical Society of America, 1993. 584 p.
  • 22
    Reale FR, Griffin TW, Compton JM, Graham S, Townes PL, Bogden A. Characterization of a human malignant mesothelioma cell line (H-MESO-1): a biphasic solid and ascitic tumor model. Cancer Res 1987; 47: 3199205.
  • 23
    de Bruijn P, Verweij J, Loos WJ, Kolker HJ, Planting AS, Nooter K, Stoter G, Sparreboom A. Determination of doxorubicin and doxorubicinol in plasma of cancer patients by high-performance liquid chromatography. Anal Biochem 1999; 266: 21621.
  • 24
    Burden DA, Osheroff N. Mechanism of action of eukaryotic topoisomerase II and drugs targeted to the enzyme. Biochim Biophys Acta 1998; 1400: 13954.
  • 25
    Swift LP, Rephaeli A, Nudelman A, Phillips DR, Cutts SM. Doxorubicin–DNA adducts induce a non-topoisomerase II-mediated form of cell death. Cancer Res 2006; 66: 486371.
  • 26
    Rdzanek M, Fresco R, Pass HI, Carbone M. Spindle cell tumors of the pleura: differential diagnosis. Semin Diagn Pathol 2006; 23: 4455.
  • 27
    Martarelli D, Catalano A, Procopio A, Orecchia S, Libener R, Santoni G. Characterization of human malignant mesothelioma cell lines orthotopically implanted in the pleural cavity of immunodeficient mice for their ability to grow and form metastasis. BMC Cancer 2006; 6: 130136.
  • 28
    Linden CJ. Response to doxorubicin and cyclophosphamide of a human pleural mesothelioma clinically and as a xenograft in nude rats. In Vivo 1990; 4: 559.
  • 29
    Kobayashi M, Takeuchi T, Ohtsuki Y. Establishment of three novel human malignant pleural mesothelioma cell lines: morphological and cytogenetical studies and EGFR mutation status. Anticancer Res 2008; 28: 197208.
  • 30
    Matsuzaki Y, Tomita M, Shimizu T, Hara M, Ayabe T, Onitsuka T. Induction of apoptosis by intrapleural perfusion hyperthermo-chemotherapy for malignant pleural mesothelioma. Ann Thorac Cardiovasc Surg 2008; 14: 1615.
  • 31
    Mossman BT, Gee JB. Asbestos-related diseases. N Engl J Med 1989; 320: 172130.
  • 32
    Robinson BW, Lake RA. Advances in malignant mesothelioma. N Engl J Med 2005; 353: 1591603.
  • 33
    Beck J, Vartuli J, Roth W, Leonowicz M, Kresge C, Schmitt K, Chu C, Olson D, Sheppard E. A new family of mesoporous molecular sieves prepared with liquid crystal templates. J Am Chem Soc 1992; 114: 1083443.
  • 34
    Kresge C, Leonowicz M, Roth W, Vartuli J, Beck J. Ordered mesoporous molecular sieves synthesized by a liquid-crystal template mechanism. Nature 1992; 359: 7102.
  • 35
    Slowing, II, Vivero-Escoto JL, Wu CW, Lin VS. Mesoporous silica nanoparticles as controlled release drug delivery and gene transfection carriers. Adv Drug Deliv Rev 2008; 60: 127888.
  • 36
    Vallet-Regi M, Balas F, Arcos D. Mesoporous materials for drug delivery. Angew Chem Int Ed Engl 2007; 46: 754858.
  • 37
    Vinu A, Hossain KZ, Ariga K. Recent advances in functionalization of mesoporous silica. J Nanosci Nanotechnol 2005; 5: 34771.
  • 38
    Huang X, Halicka HD, Traganos F, Tanaka T, Kurose A, Darzynkiewicz Z. Cytometric assessment of DNA damage in relation to cell cycle phase and apoptosis. Cell Prolif 2005; 38: 22343.
  • 39
    Zhao Y, You H, Yang Y, Wei L, Zhang X, Yao L, Fan D, Yu Q. Distinctive regulation and function of PI 3K/Akt and MAPKs in doxorubicin-induced apoptosis of human lung adenocarcinoma cells. J Cell Biochem 2004; 91: 62132.
  • 40
    Sabatino MA, Previdi S, Broggini M. In vivo evaluation of the role of DNp73alpha protein in regulating the p53-dependent apoptotic pathway after treatment with cytotoxic drugs. Int J Cancer 2007; 120: 50613.
  • 41
    Benard J, Douc-Rasy S, Ahomadegbe JC. TP53 family members and human cancers. Hum Mutat 2003; 21: 18291.
  • 42
    Stiewe T, Putzer BM. Role of p73 in malignancy: tumor suppressor or oncogene? Cell Death Differ 2002; 9: 23745.
  • 43
    Monte M, Benetti R, Collavin L, Marchionni L, Del Sal G, Schneider C. hGTSE-1 expression stimulates cytoplasmic localization of p53. J Biol Chem 2004; 279: 1174452.
  • 44
    Xiong XB, Huang Y, Lu WL, Zhang X, Zhang H, Nagai T, Zhang Q. Intracellular delivery of doxorubicin with RGD-modified sterically stabilized liposomes for an improved antitumor efficacy: in vitro and in vivo. J Pharm Sci 2005; 94: 178293.
  • 45
    Gabizon AA, Barenholz Y, Bialer M. Prolongation of the circulation time of doxorubicin encapsulated in liposomes containing a polyethylene glycol-derivatized phospholipid: pharmacokinetic studies in rodents and dogs. Pharm Res 1993; 10: 7038.
  • 46
    Barraud L, Merle P, Soma E, Lefrancois L, Guerret S, Chevallier M, Dubernet C, Couvreur P, Trepo C, Vitvitski L. Increase of doxorubicin sensitivity by doxorubicin-loading into nanoparticles for hepatocellular carcinoma cells in vitro and in vivo. J Hepatol 2005; 42: 73643.
  • 47
    Lu P. Monitoring cardiac function in patients receiving doxorubicin. Semin Nucl Med 2005; 35: 197201.